Clinical Trial of Thermal Pulsation (LipiFlow) in Meibomian Gland Dysfunction With Preteatment Meibography

Zhao, Yang; Veerappan, Anuradha; Yeo, Sharon; Rooney, David; Acharya, U. Rajendra; Tan, Jen Hong; Tong, Louis

doi:10.1097/icl.0000000000000228

Cited by 65 publications

(72 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many studies [9][10][11][12][13][14][15][16][17][18][19] have reported that a single LipiFlow® treatment had a statistically significant greater reduction in dry eye symptoms than warm compresses at 1 month until 1 year post-treatment. In contrast to those findings, the results of the present study were the same as those of other reports 16,25 that did not demonstrate a statistically significant difference in the dry eye symptoms between the single LipiFlow® treatment and the twice-daily warm compresses, nor in the number of EMGs and LLTs, despite a tendency to improve those three parameters in the patients receiving the LipiFlow® treatment. The current study could not demonstrate a statistical difference in the dry eye symptoms of both treatments, and the mean SPEED scores found in this study were less than those reported by other researches.…”

Section: Discussionsupporting

confidence: 86%

Comparison of an Automated Thermodynamic Treatment System (LipiFlow) and Warm Compresses for the Treatment of Moderate Severity of Meibomian Gland Dysfunction

Booranapong¹

2020

Smj

View full text Add to dashboard Cite

Objective: To compare the efficacies of a single thermodynamic treatment system (LipiFlow®) and warm compresses used for 3 months in patients with a moderate severity of meibomian gland dysfunction (MGD). Methods: This prospective, randomized, controlled clinical study enrolled 28 patients (22 females, 6 males; mean age, 53.9 ± 14.8 years) diagnosed as having moderate MGD by plugging at the meibomian gland orifices between one-third and two-thirds of lid margins and at least one of the following: a Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire score of 6-12; a lipid layer thickness (LLT) score of 40-70 Interferometric Color Units; upper eyelid meiboscore of 1-2; and 3-6 expressible meibomian glands (EMGs) in the lower eyelid. Both eyes of each patient were randomized into study and control eyes. Study eyes were treated with a single, 12-minute LipiFlow® system, while control eyes received 5-minute warm compresses twice daily for 3 months. The dry eye symptoms, the number of EMGs, and LLTs were evaluated. Results: There were no significant differences in the dry eye symptoms, number of EMGs, and LLTs for both groups at baseline and at each follow-up. However, the total SPEED scores for the LipiFlow® group reduced significantly from baseline at each follow-up until 6 months. As to the warm compress group, the total SPEED scores reduced significantly from baseline at each follow-up until 3 months. Conclusion: The single LipiFlow® treatment and twice-daily warm compresses relieved the dry eye symptoms of patients with a moderate severity of MGD compared with their baseline symptoms, despite no statistical differences in the dry eye symptoms, number of EMGs, and LLTs of both treatments.

show abstract

Section: Discussionsupporting

confidence: 86%

Comparison of an Automated Thermodynamic Treatment System (LipiFlow) and Warm Compresses for the Treatment of Moderate Severity of Meibomian Gland Dysfunction

Booranapong¹

2020

Smj

View full text Add to dashboard Cite

show abstract

“…9,10 The SingHealth Centralized Institutional Review Board has approved this study, and the Tenets of the Declaration of Helsinki were followed. From February 2012 to March 2013, all patients who met the eligibility criteria at the dry eye clinic in Singapore National Eye Center went through study briefing and were invited for screening.…”

Section: Study Design and Participantsmentioning

confidence: 99%

“…9 The clinical efficacy of Lipiflow, a form of thermopulsation treatment compared with warm towel, was also examined. 10 However, none of these reports have included the effect of lid warming on TE rates. The aim of the current report is to establish the longitudinal effects of eyelid warming on TE rates with eyelid warming treatment over 12 weeks of treatment period.…”

mentioning

confidence: 99%

Longitudinal Changes in Tear Evaporation Rates After Eyelid Warming Therapies in Meibomian Gland Dysfunction

Yeo

Tan

Acharya

et al. 2016

Invest. Ophthalmol. Vis. Sci.

Self Cite

View full text Add to dashboard Cite

Citation: Yeo S, Tan JH, Acharya UR, Sudarshan VK, Tong L. Longitudinal changes in tear evaporation rates after eyelid warming therapies in meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2016;57:197457: -198157: . DOI:10.1167 PURPOSE. Lid warming is the major treatment for meibomian gland dysfunction (MGD). The purpose of the study was to determine the longitudinal changes of tear evaporation after lid warming in patients with MGD.METHODS. Ninety patients with MGD were enrolled from a dry eye clinic at Singapore National Eye Center in an interventional trial. Participants were treated with hot towel (n ¼ 22), EyeGiene (n ¼ 22), or Blephasteam (n ¼ 22) twice daily or a single 12-minute session of Lipiflow (n ¼ 24). Ocular surface infrared thermography was performed at baseline and 4 and 12 weeks after the treatment, and image features were extracted from the captured images.RESULTS. The baseline of conjunctival tear evaporation (TE) rate (n ¼ 90) was 66.1 6 21.1 W/ min. The rates were not significantly different between sexes, ages, symptom severities, tear breakup times, Schirmer test, corneal fluorescein staining, or treatment groups. Using a general linear model (repeat measures), the conjunctival TE rate was reduced with time after treatment. A higher baseline evaporation rate ( ‡66 W/min) was associated with greater reduction of evaporation rate after treatment. Seven of 10 thermography features at baseline were predictive of reduction in irritative symptoms after treatment.CONCLUSIONS. Conjunctival TE rates can be effectively reduced by lid warming treatment in some MGD patients. Individual baseline thermography image features can be predictive of the response to lid warming therapy. For patients that do not have excessive TE, additional therapy, for example, anti-inflammatory therapy, may be required. (ClinicalTrials.gov number, NCT01683318 and NCT01448369.)

show abstract

“…[113,115] A clinical trial revealed that LipiFlow was able to improve symptoms of ocular irritation, and subsequently in 2011, the FDA approved LipiFlow as a medical device. [116,117] Although the treatment is an effective therapy for some patients, it is still not widely available due to its high cost. [117] Hence, additional numerous topical cost-effective pharmaceutical agents are being screened as a potential therapy for DED.…”

Section: Ocular Diseasesmentioning

confidence: 99%

Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation

Ratay

Bellotti

Gottardi³

et al. 2017

Adv Healthcare Materials

View full text Add to dashboard Cite

Dry eye disease (DED), age-related macular degeneration (AMD), and Uveitis are ocular diseases that significantly affect the quality of life of millions of people each year. In these diseases, the action of chemokines, pro-inflammatory cytokines, and immune cells drives a local inflammatory response that results in ocular tissue damage. Multiple therapeutic strategies have been developed to either address the symptoms or abate the underlying cause of these diseases. Herein, we will review the challenges to deliver drugs to the relevant location in the eye for each of these diseases as well as current and innovative therapeutic approaches that attempt to restore homeostasis within the ocular microenvironment.

show abstract

Clinical Trial of Thermal Pulsation (LipiFlow) in Meibomian Gland Dysfunction With Preteatment Meibography

Abstract: Supplemental Digital Content is Available in the Text.

Cited by 65 publications

References 38 publications

Comparison of an Automated Thermodynamic Treatment System (LipiFlow) and Warm Compresses for the Treatment of Moderate Severity of Meibomian Gland Dysfunction

Comparison of an Automated Thermodynamic Treatment System (LipiFlow) and Warm Compresses for the Treatment of Moderate Severity of Meibomian Gland Dysfunction

Longitudinal Changes in Tear Evaporation Rates After Eyelid Warming Therapies in Meibomian Gland Dysfunction

Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation

Contact Info

Product

Resources

About